Melanotan II

Mechanism of action

Melanotan II (MT-II, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2) is a cyclic heptapeptide synthesised by systematic medicinal-chemistry optimisation of the α-melanocyte-stimulating hormone (α-MSH) sequence at the University of Arizona in the 1980s (Al-Obeidi, Hadley, Hruby, and colleagues). The molecular design cyclised the α-MSH backbone through an Asp-Lys amide bridge to increase potency and metabolic stability, with additional substitutions (N-terminal acetylation with norleucine at position 1 instead of native methionine, D-phenylalanine at position 4 instead of native L-phenylalanine) to further optimise binding affinity and protease resistance. The result is a compound approximately 1000-fold more potent than native α-MSH on melanogenic endpoints while retaining broad melanocortin-receptor activity. Melanotan II is a non-selective full agonist across the melanocortin receptor family, engaging MC1R (skin pigmentation), MC3R and MC4R (central appetite, energy expenditure, and sexual function), and MC5R (exocrine function). This non-selectivity — while pharmacologically clean in the sense that it produces predictable receptor engagement — creates the multi-effect phenotype that has both driven its research and grey-market use and complicated its safety profile. MC1R activation on melanocytes is the intended pigmentation effect. Increased cAMP signalling drives MITF-mediated tyrosinase expression, promoting eumelanin (dark pigmentation) synthesis over pheomelanin. The result is progressive skin darkening with repeated dosing, often initially manifested as increased freckling and darkening of existing moles before general skin tone changes. Hair pigmentation may also be affected. The pigmentation effect is durable — persisting for weeks after discontinuation as melanin turns over in the epidermis. MC4R activation in central sexual-function circuits (hypothalamic paraventricular nucleus, medial preoptic area, brainstem) produces the sexual-arousal and erectile-function effects that were originally unexpected during clinical research and led to the subsequent PT-141/Bremelanotide development programme. In male users these effects manifest as spontaneous erections; in female users as sexual arousal. The effects are variable — some individuals experience prominent sexual effects, others minimal — reflecting individual variation in central melanocortin-system responsiveness. MC4R activation also affects appetite (typically appetite suppression), energy expenditure (modest increase), and cardiovascular sympathetic tone (modest blood pressure and heart rate elevation). MC3R and MC5R effects contribute additional metabolic and exocrine modulation. The multi-receptor engagement produces a complex phenotype that goes well beyond the intended pigmentation effect. A specific safety concern with Melanotan II is the effect on existing melanocytic naevi (moles). MC1R activation drives melanogenesis in all melanocytes including those in existing naevi, producing darkening and enlargement of moles that mimics changes indicative of melanoma progression. Case reports of atypical mole changes, dysplastic naevi development, and (in rare cases) melanoma diagnoses associated with Melanotan II use have generated substantial dermatological and regulatory concern. Whether Melanotan II directly promotes melanoma or merely darkens existing melanocytes (making pre-existing lesions more visible and easier to identify as concerning) is debated — but the effect on melanocytic naevus appearance is real and important.

The observation of unexpected sexual-arousal effects during early Melanotan II clinical exploration in the 1990s led directly to the Palatin Technologies medicinal-chemistry programme that produced PT-141/Bremelanotide as a sexual-function-optimised derivative — subsequently FDA-approved as Vyleesi in 2019. The MHRA and other regulatory bodies have consistently warned against Melanotan II use given the associated dermatological (naevus/melanoma) safety concerns.

— Notable finding

Research history

Melanotan II was developed at the University of Arizona in the 1980s by Ana Maria de L. Castrucci, Vincent J. Hruby, Mac E. Hadley, and colleagues as a synthetic α-MSH analogue optimised for pigmentation-inducing potency and metabolic stability. The original goal was to develop a systemic pigmentation-inducing agent that could function as a preventive against UV-induced skin damage — increasing endogenous melanin protection before UV exposure and reducing skin cancer risk in populations at elevated risk. The academic development programme achieved substantial pharmacological characterisation but did not advance to commercial clinical development. During the early clinical exploration of Melanotan II, the unexpected sexual-function effects were observed and characterised. This observation motivated the Palatin Technologies medicinal-chemistry programme that produced PT-141/Bremelanotide as a Melanotan II derivative optimised for sexual-function pharmacology with reduced pigmentation activity. The Melanotan II parent compound was not advanced commercially by any pharmaceutical sponsor — despite the academic development it never entered a formal Phase III programme. Melanotan II entered the grey-market cosmetic-tanning space in the mid-2000s, distributed through unofficial internet channels for skin-darkening use in fair-skinned individuals seeking bronze skin tones without UV exposure. The market has been substantial, driven by cosmetic demand and by the availability of research-chemical-grade material at moderate cost. Grey-market use spans North America, Europe (including the UK), and Australia. Regulatory responses have been generally negative. The UK MHRA has issued multiple public warnings about unlicensed Melanotan II use, citing both the intrinsic pharmacological safety concerns (particularly the melanoma concern) and the quality-assurance concerns of grey-market unregulated supply chains. The FDA has similarly warned against Melanotan II use. Australia's TGA has taken enforcement action against unauthorised supply. Despite these regulatory positions, grey-market use has persisted. Dermatology case reports of atypical mole changes and (in rare cases) melanoma diagnoses associated with Melanotan II use have accumulated across the 2010s and into the 2020s, reinforcing the dermatological concern about the compound's pigmentation-inducing pharmacology in individuals with existing melanocytic naevi. The compound remains scientifically interesting for melanocortin-system research but the safety concerns have prevented any legitimate clinical-development trajectory.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

Melanotan II has one of the more concerning safety profiles of any compound on this site, reflecting multiple mechanisms of potential harm and the specific concern about melanoma risk. The commonly reported adverse events include nausea (frequent, particularly during dose escalation), flushing, spontaneous erections in male users, appetite suppression, headache, transient hypertension, and injection-site reactions. Skin hyperpigmentation is the intended effect but often develops in patchy or asymmetric patterns that can be cosmetically undesirable. The principal specific safety concern is the effect on melanocytic naevi and the theoretical melanoma risk. MC1R activation drives melanogenesis in all melanocytes including those in existing naevi. Case reports have documented atypical mole changes, dysplastic naevi development, and (rare) melanoma diagnoses associated with Melanotan II use. Dermatology surveillance of Melanotan II users has become standard practice in jurisdictions where use is prevalent. Whether Melanotan II directly promotes melanoma or merely alters the appearance of pre-existing lesions is scientifically debated, but the concern is substantial enough that regulatory bodies uniformly advise against use. Cardiovascular effects — modest but consistent blood pressure elevation and heart rate increase — parallel those documented for PT-141 (the Melanotan II derivative). Chronic use could theoretically contribute to hypertensive complications in susceptible individuals. Metabolic effects include appetite suppression that can be substantial. Some users have used Melanotan II specifically for weight-loss effects — an off-label use with significant safety concerns given the broader melanocortin-system pharmacology. Grey-market supply quality is a significant additional concern. Unregulated supply chains produce material of variable purity, potency, and identity. Cases of contamination with other compounds (including bacterial contamination from inadequate sterility during manufacture or reconstitution) have been reported. Sterile technique in reconstitution is often inadequate in grey-market use, contributing to injection-site infection and abscess risk. Serious adverse events attributable to Melanotan II include the melanoma concern (rare but substantial), rhabdomyolysis (rare case reports), cardiovascular events in susceptible individuals, and abscess/sepsis from non-sterile injection technique. The MHRA and other regulatory bodies have publicly recommended against Melanotan II use in unmistakable terms. The safety concerns are substantial enough that this profile is included as a research reference and safety-warning framework rather than as a research-use recommendation.

UK regulatory status

Melanotan II is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation in any jurisdiction. It is not a controlled substance under the Misuse of Drugs Act 1971. The MHRA has issued multiple explicit public warnings about unlicensed Melanotan II use in the UK, citing both intrinsic pharmacological safety concerns (particularly the melanoma concern from MC1R activation of existing naevi) and quality-assurance concerns of grey-market unregulated supply chains. Supply of Melanotan II for human use in the UK engages the Human Medicines Regulations 2012 and is generally an offence; MHRA enforcement actions against Melanotan II suppliers have been recurring. Despite the MHRA position, grey-market Melanotan II use in the UK has persisted through online research-chemical and cosmetic-supply channels. The MHRA enforcement position is that supply is illegal but individual possession/use is not itself a criminal offence — the regulatory focus is on the supply side. Research-grade material for legitimate in-vitro and animal research is available from research-chemical suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. Melanotan II is not currently on the WADA Prohibited List. Its mechanism (pigmentation and sexual function) does not fall within any current WADA category. For animal research under ASPA, Melanotan II work in vertebrates requires standard project and personal licences. Given the specific melanoma concerns and the MHRA public warnings, this profile is included as a research-and-safety reference rather than as a use-facilitation document.

Frequently asked questions